Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

SynDevRx is focused on developing drug candidates for metabo-oncology and other disease states related to cancer and metabolic dysfunction.

The first indication for SDX-7320 is in post-menopausal HR+, Her2- metastatic breast cancer with the PIK3CA mutation in combination with standard of care treatment.  We are currently planning on starting this Phase 1b/2 combination study in mid-2020.

Clinical trials for other indications (e.g. metastatic colorectal, hepatacellular carcinoma (liver cancer), NSCLC) will follow later in 2020.

View Clinical Trials